These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27221870)

  • 1. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H; Pradjatmo H
    Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H; Maurer KA; Nutter B; Rose PG
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
    Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
    Al-Badawi IA; Munkarah AR; Tulbah A; Babic II; Al Husaini H; Ahmad S
    Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension.
    Sakurai M; Satoh T; Matsumoto K; Michikami H; Nakamura Y; Nakao S; Ochi H; Onuki M; Minaguchi T; Yoshikawa H
    Int J Gynecol Cancer; 2015 May; 25(4):593-8. PubMed ID: 25756402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prognostic factors on survival rates in patients with ovarian carcinoma.
    Arikan SK; Kasap B; Yetimalar H; Yildiz A; Sakarya DK; Tatar S
    Asian Pac J Cancer Prev; 2014; 15(15):6087-94. PubMed ID: 25124578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
    Sabatier R; Calderon B; Lambaudie E; Chereau E; Provansal M; Cappiello MA; Viens P; Rousseau F
    Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
    Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
    In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
    Jernigan AM; Mahdi H; Rose PG
    Int J Gynecol Cancer; 2015 Sep; 25(7):1232-8. PubMed ID: 26067864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
    Shaboodien R; Diamantis N; Blagden S; Gabra H; Agarwal R
    Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.
    Ose J; Schock H; Tjønneland A; Hansen L; Overvad K; Dossus L; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopolou A; Benetou V; Lagiou P; Masala G; Tagliabue G; Tumino R; Sacerdote C; Mattiello A; Bueno-de-Mesquita HB; Peeters PH; Onland-Moret NC; Weiderpass E; Gram IT; Sánchez S; Obon-Santacana M; Sànchez-Pérez MJ; Larrañaga N; Castaño JM; Ardanaz E; Brändstedt J; Lundin E; Idahl A; Travis RC; Khaw KT; Rinaldi S; Romieu I; Merritt MA; Gunter MJ; Riboli E; Kaaks R; Fortner RT
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):951-61. PubMed ID: 25855626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.